A5032115602- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Neuroscience of respiration and sleep
- High Altitude and Hypoxia
- Heme Oxygenase-1 and Carbon Monoxide
- Cardiovascular Function and Risk Factors
- Diabetes Management and Education
- Sleep and Wakefulness Research
- Mobile Health and mHealth Applications
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Dietary Effects on Health
- Metabolism, Diabetes, and Cancer
- Obstructive Sleep Apnea Research
- Gastrointestinal disorders and treatments
- Sphingolipid Metabolism and Signaling
- Iron Metabolism and Disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pregnancy and preeclampsia studies
- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Cardiovascular and Diving-Related Complications
- Hepatitis Viruses Studies and Epidemiology
- Hemoglobinopathies and Related Disorders
Medtronic (Switzerland)
2013-2025
Northwestern Medicine
2025
General Hospital of Drama
2025
Medtronic (Netherlands)
2015-2024
Instituto del Mar del Peru
1998-2022
Hospital General de México
2002-2020
Bakken Museum
2014-2018
Universidad de Valladolid
1997-2011
Centro de Investigación Biomédica en Red
2011
Hospital de São José
2010
The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. preliminary performance of the in real-world settings was evaluated.
Abstract Aim To investigate real‐world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger older than 15 years with type 1 diabetes (T1D). Materials Methods Data uploaded from 27 August 2020 to 22 July 2021 were aggregated retrospectively analysed based on self‐reported age (≤15 >15 years) for three cohorts: (a) post‐AHCL initiation, (b) 6‐month longitudinal initiation (c) pre‐ versus initiation. Analyses included mean...
Automated insulin delivery systems have improved glycaemic control in people with type 1 diabetes mellitus. The analysis investigated predictors of sensor glucose time-in-range (TIR; 70-180 mg/dl) based on real-world use the MiniMed 780G advanced hybrid closed-loop (AHCL) system.Data uploaded by system users from August 2020-July 2021 were analysed using univariate and multivariable models to identify baseline, demographic characteristics associated TIR after AHCL initiation (post-AHCL)....
We studied time in tight range (TITR) (70-140 mg/dL) real-world users of the MiniMed 780G system (MM780G).
The present report celebrates the benchmarking of 100,000 MiniMed™ 780G system users in Europe, Middle East, and Africa (EMEA) summarizes major insights into usability outcomes this system.
To investigate the impact of continuous glucose monitoring (CGM) on health-related quality life (HRQOL), treatment satisfaction (TS) medical resource use, and indirect costs in SWITCH study. was a multicentre, randomized, crossover Patients with type 1 diabetes (n = 153) using subcutaneous insulin infusion (CSII) were randomized to 12 month sensor-On/Off or sensor-Off/On sequence (6 months each treatment), 4-month washout between periods. HRQOL children TS adults measured validated...
Sensor-augmented pump (SAP) therapy can improve glycemic control, compared with multiple daily insulin injections or alone, without increasing the risk of hypoglycemia.
We studied real-world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), the effect each technology iteration MM on glycaemic control (technology analysis).CareLink data August 2020 to September 2022 were extracted. Endpoints included continuous glucose monitoring metrics. For geographical analysis, aggregated endpoints for MM780G calculated. user outcomes compared with when same individuals still using MM640G or MM670G system.On...
The concept of maintaining blood glucose levels within the 70-180 mg/dL range, known as time-in-range, has raised questions regarding its representation true physiological euglycemia. Some have speculated that focusing on time spent 70-140 introduced in tight range (TITR) through International Consensus statement, could serve a more precise metric for assessing normoglycemia individuals with type 1 diabetes. This article delves into current status TITR an emerging marker and explores how...
The mechanisms involved in hypoxic pulmonary vasoconstriction (HPV) are not yet fully defined. aim of the study was to determine role protein kinase C ζ (PKCζ) and neutral sphingomyelinase (nSMase) HPV. Ceramide content measured by immunocytochemistry voltage-gated potassium channel (KV) currents were recorded patch clamp technique isolated rat artery smooth muscle cells (PASMC). Contractile responses analysed arteries mounted a wire myograph. Pulmonary pressure anesthetized open-chest rats....
Aims To compare insulin pump therapy and multiple daily injections ( MDI ) in patients with type 2 diabetes receiving basal prandial analogues. Methods After a 2‐month dose‐optimization period, 331 glycated haemoglobin HbA1c levels ≥8.0% ≤12% were randomized to or continued for 6 months [randomization phase RP )]. The group was subsequently switched during 6‐month continuation CP ). primary endpoint the between‐group difference change mean from baseline end of . Results at 9% both groups. At...
To evaluate the real-world performance of MiniMed 670G system in Europe, individuals with diabetes.Data uploaded from October 2018 to July 2020 by living Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage time spent within (TIR), below (TBR) above (TAR) glycaemic ranges, use insulin consumed users 10 or more days sensor data after initial Auto Mode start determined. Another analysis based on suboptimally (GMI > 8.0%) well-controlled <...
To analyse blood glucose control according to continuous monitoring use in data from the CareLink database, and identify factors associated with continuation of sensor during sensor-augmented pump therapy.The analysis used 10 501 people Type 1 2 diabetes mellitus, whom 7916 (61.7%) had sensors for ≥ 15 days any 6-month period over a 2-year observation period. Data were analysed extent ( < 25%, 25-49%, 50-74% 75% time). Time discontinuation was also new users sensors.Compared patients lowest...
Abstract Aims Large‐scale studies on the effectiveness of automated insulin delivery (AID) systems in older people with type 1 diabetes are still limited. A multinational, retrospective, real‐world study was conducted to examine performance MiniMed™ 780G advanced hybrid closed‐loop system users aged ≥56 years compared those 16–55 years. Materials and Methods Data from 35 366 7415 were included. The main outcome time range 70–180 mg/dL (TIR); other continuous glucose monitoring (CGM) metrics...
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin required in significant portion people with T2D, despite recent developments antidiabetic medications. This study analyzes glycemic outcomes automated delivery (AID) users T2D different requirements. Methods: retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 April 2024). Four cohorts were identified based on phenotypes T2D: (A)...
Art-based interventions are recognised for their mental health (MH) benefits. This study assessed the changes in symptoms of anxiety and depression young adults experiences after participating a three-session mixed arts workshop. non-controlled trial included pre-intervention two post-intervention measurements (PHQ-8) (GAD-7) exit interviews with participants facilitators. The registration number this is ISRCTN16079466. Thirty-seven participated study. Over 78% reduced PHQ-8 GAD-7 scores by...